Plasma neurofilament light chain level is not a biomarker of Charcot–Marie–Tooth disease progression: Results of 3‐year follow‐up study
European Journal of Neurology · 2023
DOI: 10.1111/ene.15858 ↗At a glance
Journal article in European Journal of Neurology, 2023. Written by Signe Setlere and 7 co-authors. Institution: Department of Neurology and Neurosurgery, Children's Clinical University Hospital, Riga, Latvia. Major MEDLINE topics: Charcot-Marie-Tooth Disease. Cited 12 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: European Research Council, Vetenskapsrådet, H2020 European Research Council.
Abstract (original language)
Background and purpose Charcot–Marie–Tooth disease (CMT) is a hereditary, slowly progressive neuropathy. Currently, there are no effective pharmacological treatments or sensitive disease activity biomarkers available. The aim of this study was to demonstrate the change in plasma neurofilament light chain (NfL) over time in a CMT cohort and analyse the association between CMT severity and NfL level.
Methods
Initially, 101 CMT patients and 64 controls were enrolled in the study. Repeated evaluation was performed in 73 patients and 28 controls at a 3‐year interval. Disease severity assessment included clinical evaluation with CMT Neuropathy Score version 2 (CMTNSv2). Plasma NfL concentration was measured using the Simoa (single molecule array) NfL assay.
Results
Plasma NfL concentration was increased in the CMT group compared with controls ( p < 0.001). Overall NfL level increased over the 3‐year interval in both CMT ( p = 0.012) and control ( p = 0.001) groups. However, in 22 of 73 CMT patients and seven of 28 controls, the NfL level decreased from the baseline. Analysing the association between 3‐year change in plasma NfL and disease severity (CMTNSv2), there was no correlation in the CMT group ( r = 0.228, p = 0.052) or different CMT subgroups.
Conclusions
Our study verifies increased plasma NfL concentrations in patients with CMT compared with controls. Longitudinal 3‐year data showed a variable change in NfL levels between CMT subtypes. There was no association between change in NfL over time and disease severity. These findings suggests that NfL is not a biomarker for CMT progression.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology and Neurosurgery, Children's Clinical University Hospital, Riga, Latvia.
- Department of Doctoral Studies, Riga Stradins University, Riga, Latvia.
- Faculty of Medicine, Riga Stradins University, Riga, Latvia.
- Department of Biology and Microbiology, Riga Stradins University, Riga, Latvia.
- Outpatient Service Centre, Pauls Stradins Clinical University Hospital, Riga, Latvia.
- Scientific Laboratory of Molecular Genetics, Riga Stradins University, Riga, Latvia.
ORCID profiles: Signe Setlere
Funding
- European Research Council
- Vetenskapsrådet
- H2020 European Research Council
- Alzheimer's Drug Discovery Foundation
Cite
APA
Setlere, S., Grosmane, A., Kurjane, N., Gailite, L., Rots, D., Blennow, K., Zetterberg, H., & Kenina, V. (2023). Plasma neurofilament light chain level is not a biomarker of Charcot–Marie–Tooth disease progression: Results of 3‐year follow‐up study. European Journal of Neurology. https://doi.org/10.1111/ene.15858
Vancouver
Setlere S, Grosmane A, Kurjane N, Gailite L, Rots D, Blennow K, et al. Plasma neurofilament light chain level is not a biomarker of Charcot–Marie–Tooth disease progression: Results of 3‐year follow‐up study. European Journal of Neurology. 2023. doi:10.1111/ene.15858
BibTeX
@article{Setlere2023,
author = {Setlere, Signe and Grosmane, Arta and Kurjane, Natalja and Gailite, Linda and Rots, Dmitrijs and Blennow, Kaj and Zetterberg, Henrik and Kenina, Viktorija},
title = {Plasma neurofilament light chain level is not a biomarker of Charcot–Marie–Tooth disease progression: Results of 3‐year follow‐up study},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15858}
}
EUVIMED